Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was upgraded by TheStreet from a “c” rating to a “b-” rating in a research note issued to investors on Friday.

Other equities research analysts also recently issued reports about the stock. UBS AG assumed coverage on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 29th. They issued a “buy” rating and a $138.00 price objective for the company. Stifel Nicolaus reissued a “buy” rating and set a $157.00 target price on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Jefferies Group LLC set a $120.00 target price on shares of Alexion Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, June 8th. SunTrust Banks, Inc. reissued a “buy” rating and set a $165.00 target price on shares of Alexion Pharmaceuticals in a research report on Friday. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $177.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, March 27th. Eight analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Alexion Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $156.62.

Alexion Pharmaceuticals (ALXN) traded down 0.73% during trading on Friday, reaching $125.78. The company had a trading volume of 927,063 shares. The company has a market capitalization of $28.24 billion, a price-to-earnings ratio of 59.92 and a beta of 1.38. The company has a 50-day moving average price of $112.16 and a 200 day moving average price of $122.31. Alexion Pharmaceuticals has a one year low of $96.18 and a one year high of $145.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.33. Alexion Pharmaceuticals had a net margin of 14.52% and a return on equity of 11.72%. The business had revenue of $870 million during the quarter, compared to the consensus estimate of $826.63 million. During the same period in the prior year, the firm posted $1.11 EPS. The firm’s quarterly revenue was up 24.3% compared to the same quarter last year. Analysts expect that Alexion Pharmaceuticals will post $5.32 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/07/17/alexion-pharmaceuticals-inc-alxn-stock-rating-upgraded-by-thestreet.html.

In other Alexion Pharmaceuticals news, Director Bros. Advisors Lp Baker bought 1,348,955 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Wednesday, June 14th. The shares were bought at an average price of $116.32 per share, with a total value of $156,910,445.60. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Ludwig Hantson bought 10,000 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Wednesday, June 14th. The shares were acquired at an average cost of $116.72 per share, for a total transaction of $1,167,200.00. Following the acquisition, the chief executive officer now owns 38,725 shares in the company, valued at approximately $4,519,982. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 2,019,734 shares of company stock worth $235,606,846. Corporate insiders own 4.35% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in Alexion Pharmaceuticals by 2,689.8% in the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock valued at $2,258,467,000 after buying an additional 17,960,356 shares in the last quarter. Jennison Associates LLC raised its position in Alexion Pharmaceuticals by 15.8% in the first quarter. Jennison Associates LLC now owns 9,622,914 shares of the biopharmaceutical company’s stock valued at $1,166,682,000 after buying an additional 1,309,529 shares in the last quarter. Bank of Montreal Can raised its position in Alexion Pharmaceuticals by 628.8% in the second quarter. Bank of Montreal Can now owns 1,423,318 shares of the biopharmaceutical company’s stock valued at $173,174,000 after buying an additional 1,228,025 shares in the last quarter. State Street Corp raised its position in Alexion Pharmaceuticals by 6.8% in the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock valued at $1,369,846,000 after buying an additional 718,756 shares in the last quarter. Finally, Marshall Wace North America L.P. acquired a new position in Alexion Pharmaceuticals during the first quarter valued at approximately $65,219,000. 94.75% of the stock is currently owned by institutional investors.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.